Immune Modifying Nanoparticles Reduce Heart Attack Damage - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Immune Modifying Nanoparticles Reduce Heart Attack Damage


Cour Pharmaceutical Development Company, a biopharmaceutical company, has published new data showing that its proprietary nanoparticle therapy could potentially reduce inflammation and promote tissue repair and regeneration in patients who have had a heart attack.

In this study, published in Science Translational Medicine, animal models were injected with Immune Modifying Nanoparticles (IMP) following a heart attack. Scientists found that the size of the heart lesions was reduced by half and as a result, the heart could pump significantly more blood. IMP treatment demonstrated the ability to reduce inflammation and promote regeneration in all models tested.

"This is the first therapy that specifically targets a key driver of the inflammation that occurs after a heart attack," said Daniel Getts, chief scientific officer at Cour, in a press statement. "There is no other therapy on the horizon that can protect the heart from the aggressive immune cell infiltration that causes so much damage."

"IMP therapy represents a significant step toward the next generation of immune modulating agents," said John J. Puisis, CEO of Cour, in the same release. He added, "Our first priority as a company is to bring IMPs to patients who've suffered acute myocardial infarction, where we see a tremendous opportunity to improve clinical outcomes and quality of life."

The nanoparticles are proprietary compositions based on poly-lactic-co-glycolic acid, a biocompatible and biodegradable substance already approved by the FDA for use in a range of therapeutics. Efficacy has also been demonstrated in several other inflammatory models, such as West Nile virus, encephalitis, peritonitis, multiple sclerosis, and inflammatory bowel disease.

Source: Cour Pharmaceutical Development Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here